Press Releases and Blog
Blog
Reminder: Pharmacy Network Design Saves Money
Pharmacy benefit managers (PBMs) continue to work every day to lower prescription drug costs, leading to savings of an average of $1,040 per person per year. While
Recent Headlines Showcase Positive Progress Toward Cracking Down on Big Pharma’s Patent Abuse in U.S. Senate
Lawmakers’ Focus Should Remain on Anti-Competitive Drug Company Tactics that Keep Prices High, Reject Pharma-Backed Anti-PBM Agenda The U.S. Senate recently took a step
ICYMI: Leading Economist Debunks Misconceptions Surrounding the PBM-Pharmacy Relationship
In case you missed it, a recent study conducted by Dennis Carlton, Ph.D., professor emeritus at the University of Chicago Booth School of Business and
Big Pharma Highlights How PBMs Secure Significant Savings on Prescription Drugs
Recently, several of the largest pharmaceutical manufacturers explained how pharmacy benefit managers (PBMs) are lowering prescription drug costs, specifically the highly priced GLP-1 weight loss
Former U.S. Senator Toomey And Competitive Enterprise Institute Debunk Fundamentally Flawed FTC Report On PBMs
In case you missed it, former U.S. Senator Pat Toomey (R-PA) and senior fellow at the Competitive Enterprise Institute (CEI) Joel Zinberg, MD discuss the
ICYMI: Former DOJ Economist Finds PBMs Foster Competition, Reduce Drug Costs In New Report
In case you missed it, Dennis W. Carlton, Ph.D., David McDaniel Keller Professor of Economics Emeritus at the University of Chicago Booth School of Business,
Press Releases
PCMA Statement On Biased And Incomplete Article In The New York Times
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on today’s article in The New York Times.
PCMA Launches New Campaign to Elevate the Voice of the Employer, Critical Value of the Employer-PBM Relationship
“How PBMs Work” Demonstrates How Pharmacy Benefits are Essential for Employers to Compete and Offer Affordable, High-Quality Health Care Benefits (Washington, D.C.) — The
PCMA Statement on Senate Judiciary Committee Hearing on Competition in The Prescription Drug Market
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of the U.S. Senate Committee on the Judiciary hearing, “Ensuring Affordable
PCMA Releases Statement on CMS Part D Biosimilar Substitution Announcement
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the recent announcement from the Centers for Medicare and Medicaid Services
PCMA Releases Statement on Kentucky House Bill 220
(Frankfort, KY) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the passage of House Bill 220 in Kentucky. “PCMA applauds the
PCMA Releases Statement On White House PBM Listening Session
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs. “Today’s White House listening session
ICYMI: Ike Brannon: Recently Proposed Federal And State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed
Misguided Proposals Targeting Pharmacy Benefit Companies Would Increase Prescription Drug Costs for Patients, Take Away Options From Health Plan Sponsors, Like Employers and Unions
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
ICYMI: Former U.S. Senator Pat Toomey: GOP Can’t Afford to Start 2024 with Giant Health Care Mandates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated
ICYMI: New Report Underscores That Rebates Have No Correlation With High Drug Prices
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director
ICYMI: New Public Employee Policy Research Affirms PBMs Are Essential In Administering Pharmacy Benefits, Public Sector Employers Satisfied With Their Pharmacy Benefit Companies
In case you missed it, the National Institute for Public Employee Health Care Policy recently released a report, “How Public Sector Health Care Purchasers Are
ICYMI: Former Senator Pat Toomey Cautions Congress Against Proposals Targeting Pharmacy Benefit Companies
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in
ICYMI: Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: “Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug